Evidence map›Paper›PMID 41582866›Full record

ReviewExpert reviews in molecular medicine2026

Targeting CD39 as a Therapeutic for Cancer Immunotherapy.

Zhongliang Li, Weiguo Xu, Hang Fai Kwok

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert reviews in molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zhongliang LiDepartment of Biomedical Sciences, Faculty of Health Sciences, https://ror.org/01r4q9n85University of Macau, Avenida da Universidade, Taipa, Macao and Zhuhai People's Hospital Centre for Precision Medicine, Zhuhai Clinical Medical College of Jinan University, Zhuhai, Guangdong, China.
Weiguo XuDepartment of Cerebrovascular Disease, Center of Intervention Radiology,https://ror.org/01k1x3b35Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai, Guangdong, China.
Hang Fai KwokDepartment of Biomedical Sciences, Faculty of Health Sciences, https://ror.org/01r4q9n85University of Macau, Avenida de Universidade, Taipa, Macao.ORCID 0000-0002-6349-4517

Funding

Fundo para o Desenvolvimento das Ciências e da Tecnologia 0027/2022/A1Fundo para o Desenvolvimento das Ciências e da Tecnologia 0069/2025/AFJNational Natural Science Foundation of China 62027901
6 · The paper itself

Abstract

CD39 plays a pivotal role in the ATP-to-adenosine signalling pathway, serving as a critical mediator of immune suppression within the tumour microenvironment. Increasing preclinical evidence indicates that its inhibition can restore antitumour immunity and improve the efficacy of established treatments. In this review, we summarise the biology of CD39, its role in shaping the immunosuppressive tumour microenvironment, and therapeutic strategies currently under development. We also discuss early clinical progress and safety considerations, along with major challenges and future perspectives. Targeting CD39 represents a promising strategy to overcome tumour-induced immunosuppression and ongoing advances in therapeutic development could usher in next-generation immunotherapies.

Indexed as

ApyraseImmunotherapyNeoplasmsAnimalsHumansMolecular Targeted TherapySignal TransductionTumor MicroenvironmentApyraseENTPD1 protein, humanCD39immune evasionimmune suppressionimmunotherapytumour microenvironment

Identifiers

PMID41582866
PMCPMC12935479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.